Genzyme Drug Fails to Win FDA Nod

10/6/09

The FDA turned down Genzyme’s application to market clofarabine (Clolar) for patients over age 60 with acute myeloid leukemia, saying the Cambridge, MA-based company should conduct another randomized, controlled clinical trial. The agency’s decision comes about a month after one of its advisory panels recommended the drug not be cleared for the new group of patients, saying Genzyme (NASDAQ: GENZ) lacked data. The product is already approved for a smaller population of children with leukemia.

By posting a comment, you agree to our terms and conditions.